Referred to the House Committee on Energy and Commerce.
The bill requires coverage, with no cost-sharing, of specified ‘human milk fortifier’ (donor human milk–derived nutritional products) for medically necessary infants under age 1 across Medicaid, the Children’s Health Insurance Program (CHIP), and group and individual private health plans. It defines medical necessity criteria (e.g., gestational age ≤34 weeks, birth weight under 1800 grams, or other conditions as determined by a licensed clinician) and specifies which professionals may make the determination.
Scope and legitimacy of a federal mandate on private plans: liberals and centrists accept it; conservatives see it as federal overreach.
Relative to its intended legislative type, this bill is a direct and legally specific substantive policy change that amends named statutory provisions to require no-cost coverage of defined donor human milk-derived fortifiers for specified infants across Medicaid, CHIP, and private group/individual plans, with clear effective dates.
The bill requires coverage, with no cost-sharing, of specified ‘human milk fortifier’ (donor human milk–derived nutritional products) for medically necessary infants under age 1 across Medicaid, the Children’s Health Insurance Program (CHIP), and group and individual private health plans.
It defines medical necessity criteria (e.g., gestational age ≤34 weeks, birth weight under 1800 grams, or other conditions as determined by a licensed clinician) and specifies which professionals may make the determination.
The mandate takes effect January 1, 2026 for most programs (with a timing exception for state legislation under CHIP) and applies to plan years beginning on or after January 1, 2026 for private coverage.
On content alone, the bill is a narrow, technical health benefit expansion with low ideological salience and a modest fiscal footprint limited to a small clinical population — factors that increase prospects for bipartisan support. However, it imposes new mandatory benefits across Medicaid/CHIP and private plans without appropriation or offsets, which raises fiscal and federalism concerns that can slow or block passage, especially in the Senate or as a standalone vehicle.
Relative to its intended legislative type, this bill is a direct and legally specific substantive policy change that amends named statutory provisions to require no-cost coverage of defined donor human milk-derived fortifiers for specified infants across Medicaid, CHIP, and private group/individual plans, with clear effective dates.
Scope and legitimacy of a federal mandate on private plans: liberals and centrists accept it; conservatives see it as federal overreach.
These are examples from the analysis, not a ranked list of the most-affected groups.
Scope and legitimacy of a federal mandate on private plans: liberals and centrists accept it; conservatives see it as federal overreach.
This persona would view the bill favorably as a targeted, equity-promoting health intervention that removes a financial barrier to evidence-informed neonatal nutrition for vulnerable infants.
They would see the prohibition on cost-sharing as essential to ensuring low-income families and those on Medicaid and CHIP can access donor human milk–derived fortifiers when clinicians judge them medically necessary.
They may wish the bill went further to fund milk banks, lactation support, and related maternal-child nutrition services.
This persona would generally support a narrowly tailored mandate that covers medically necessary donor human milk–derived fortifier for fragile infants, while seeking fiscal and implementation guardrails.
They would appreciate clear clinical criteria and the no-cost-sharing provision for low-income families but want an objective assessment of costs and operational feasibility before full endorsement.
They would emphasize the need for implementation details (prior authorization, fraud controls, reimbursement rates, and supply capacity) and for minimizing unintended consequences like premium increases.
This persona would be skeptical of the federal mandate requiring no-cost coverage across Medicaid, CHIP, and private plans.
While sympathetic to improving care for preterm infants, they would view the bill as federal overreach that imposes regulatory and cost burdens on states, employers, insurers, and ultimately taxpayers or premium payers.
They would press for state flexibility, clearer fiscal accounting, and limits on federal mandates to private coverage.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone, the bill is a narrow, technical health benefit expansion with low ideological salience and a modest fiscal footprint limited to a small clinical population — factors that increase prospects for bipartisan support. However, it imposes new mandatory benefits across Medicaid/CHIP and private plans without appropriation or offsets, which raises fiscal and federalism concerns that can slow or block passage, especially in the Senate or as a standalone vehicle.
The bill has not accumulated any surfaced votes yet.
Scope and legitimacy of a federal mandate on private plans: liberals and centrists accept it; conservatives see it as federal overreach.
On content alone, the bill is a narrow, technical health benefit expansion with low ideological salience and a modest fiscal footprint limi…
Relative to its intended legislative type, this bill is a direct and legally specific substantive policy change that amends named statutory provisions to require no-cost coverage of defined donor human milk-derived fort…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.